ACR Alpine Capital Research LLC grew its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 21.0% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,226,559 shares of the company's stock after purchasing an additional 386,322 shares during the period. Johnson & Johnson makes up about 7.7% of ACR Alpine Capital Research LLC's holdings, making the stock its 3rd largest holding. ACR Alpine Capital Research LLC owned about 0.09% of Johnson & Johnson worth $369,253,000 at the end of the most recent reporting period.
Other large investors also recently added to or reduced their stakes in the company. WealthTrak Capital Management LLC acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at $26,000. Conquis Financial LLC acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at $33,000. Bernard Wealth Management Corp. acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at $36,000. Highline Wealth Partners LLC raised its stake in shares of Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after acquiring an additional 86 shares in the last quarter. Finally, von Borstel & Associates Inc. acquired a new stake in shares of Johnson & Johnson in the first quarter valued at $49,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.
Johnson & Johnson Stock Performance
Shares of NYSE JNJ traded up $0.52 during midday trading on Thursday, reaching $169.62. 6,629,361 shares of the company were exchanged, compared to its average volume of 8,401,730. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The stock has a fifty day simple moving average of $155.75 and a 200 day simple moving average of $155.63. The stock has a market cap of $408.11 billion, a P/E ratio of 18.14, a PEG ratio of 2.15 and a beta of 0.41.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. The firm had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 33.07% and a net margin of 25.00%. The business's revenue was up 5.8% on a year-over-year basis. During the same quarter last year, the company posted $2.82 earnings per share. On average, research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.
Johnson & Johnson Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be given a $1.30 dividend. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 3.07%. Johnson & Johnson's payout ratio is currently 55.61%.
Wall Street Analyst Weigh In
A number of analysts have weighed in on the company. Leerink Partnrs cut Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Raymond James Financial cut their price target on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research note on Monday, April 14th. Barclays raised their price target on Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research note on Thursday, July 17th. Royal Bank Of Canada raised their price target on Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a research note on Thursday, July 17th. Finally, Bank of America raised their price target on Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a research note on Thursday, July 17th. Nine research analysts have rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $174.50.
Check Out Our Latest Research Report on JNJ
Johnson & Johnson Profile
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Further Reading
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
